SPRINT Trial Risk Stratification Calculator

Clinical calculation support · Verify results before clinical use

Patient profile and treatment target

Review selected characteristics used in the SPRINT trial and compare the trial's two systolic blood-pressure targets.

0/3 Features

SPRINT enrolled adults aged 50 years or older. Age ≥75 years was one of the qualifying increased-risk characteristics.

Chronic kidney disease status

For the SPRINT CKD entry criterion, eGFR was 20 to less than 60 mL/min/1.73 m² (polycystic kidney disease excluded). A general CKD diagnosis alone does not establish this criterion.

The SPRINT protocol's risk criterion used the Framingham 10-year cardiovascular risk estimate ≥15%, not an interchangeable ASCVD calculator output. Select the risk estimate type below.

Treatment target for comparison

These are the randomized treatment targets studied in SPRINT, not automatically appropriate targets for every individual patient.

Profile summary

Enter patient details

Complete age, kidney function category, and cardiovascular risk method to review which selected trial entry-risk characteristics are present.

Selected treatment target

Intensive strategy: target SBP <120 mmHg. This is a trial arm description, not an individualized prescription.

This tool is an educational profile summary, not a validated SPRINT risk score, treatment-effect calculator, or substitute for clinical assessment.

Clinical context

SPRINT (Systolic Blood Pressure Intervention Trial) compared an intensive systolic blood-pressure target of <120 mmHg with a standard target of <140 mmHg in selected adults with hypertension and increased cardiovascular risk, without diabetes or a history of stroke.

The original trial reported fewer major cardiovascular events and deaths in the intensive-treatment group, while some serious adverse events were more frequent. The result should not be interpreted as evidence that every patient should be treated to an SBP below 120 mmHg.

Selected increased-risk entry characteristics

CharacteristicSPRINT criterion
AgeAge ≥75 years
Chronic kidney diseaseeGFR 20 to <60 mL/min/1.73 m², excluding polycystic kidney disease
Estimated riskFramingham 10-year cardiovascular risk ≥15%
Cardiovascular diseaseClinical or subclinical cardiovascular disease other than stroke, according to the trial protocol

Important limits

  • This calculator does not assess all SPRINT inclusion or exclusion criteria, including baseline SBP, diabetes, prior stroke, symptomatic heart failure, or other protocol exclusions.
  • It does not calculate an individual absolute risk reduction, number needed to treat, or probability of benefit.
  • Clinical assessment should include measurement technique, orthostatic symptoms, frailty, comorbidities, kidney function, electrolytes, medication burden, and patient preferences.

References

SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103–2116. doi:10.1056/NEJMoa1511939 · PMID: 26551272
SPRINT Research Group. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2021;384:1921–1930. doi:10.1056/NEJMoa1901281
National Heart, Lung, and Blood Institute (NHLBI). Systolic Blood Pressure Intervention Trial (SPRINT) Study. Trial overview and key findings. Official NHLBI resource
Clinical disclaimer: This educational tool summarizes selected SPRINT trial characteristics and treatment targets. It is not a validated clinical risk score and must not be used alone to select a blood-pressure target or change treatment. SPRINT findings apply to a selected study population; assess contraindications, adverse-event risk, measurement method, and current guideline recommendations before making treatment decisions.